IDL Biotech Q3: Temporary sales drop

Research Note

2019-10-22

09:55

IDL’s third quarter was characterized by weaker sales than expected due to issues related to its former distributor for the Indonesian market. Consequently, EBIT also came in below our estimates. We comment on today’s report and the announcement of a new distributor for the Indonesian market.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.